Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03832361 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

A Phase 2 study of Endometrial Cancer, sponsored by Alessandro Santin.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
1
Study location

NCT03832361 is a Phase 2 study of Endometrial Cancer that is actively recruiting participants, run by Alessandro Santin. The registered enrollment target is 50 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03832361, a Phase 2 study of Endometrial Cancer, is actively recruiting participants, sponsored by Alessandro Santin.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).

Conditions Studied

Endometrial Cancer

Interventions

  • DRUG IMGN853

Study Locations (1)

Connecticut

  • Smilow Cancer Hospital at Yale New Haven - New Haven

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2020-07-15
Est. Completion 2028-10
Phase Phase 2

Sponsor

Alessandro Santin

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03832361

The ClinicalTrials.gov registry entry for NCT03832361 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Alessandro Santin, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which IMGN853 is the first listed.

NCT03832361 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT03832361 about?

NCT03832361 is a clinical study titled "Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer". The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).

What is the current status of trial NCT03832361?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2020-07-15. Estimated completion is 2028-10.

What conditions does trial NCT03832361 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT03832361?

The interventions under investigation include: IMGN853 (DRUG).

Who is sponsoring clinical trial NCT03832361?

This trial is sponsored by Alessandro Santin, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03832361 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometrial Cancer

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.